Evaluation of Anti-desmoglein-1 and Anti-desmoglein-3 Autoantibody Titers in Pemphigus Patients at the Time of the Initial Diagnosis and After Clinical Remission

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Nov 18

PMID 29145342

Citations 3

Authors

Irene Russo

Francesco Paolo De Siena

Andrea Saponeri

Mauro Alaibac

Affiliations

Soon will be listed here.

Abstract

It has been suggested that anti-desmoglein autoantibody titers could be helpful in follow-up and therapeutic management of pemphigus patients. However, there is no consensus regarding the relationship between anti-desmoglein autoantibody titers and clinical activity of pemphigus.The aim of our study was to evaluate if clinical remission of pemphigus relates to the presence of anti-desmoglein autoantibodies.Thirty patients with pemphigus vulgaris and 7 patients with pemphigus foliaceous were included in the study. Assessment of autoantibody titers was carried out at the time of the initial diagnosis and after the clinical remission using an enzyme-linked immunosorbent assay-based assay.Our results indicate that pemphigus clinical remission did not necessarily imply a serological remission, and consequently it is necessary to establish if withdrawal of the immunosuppressive regimen in pemphigus should be based exclusively on the achievement of clinical remission or also on the serological findings.

Citing Articles

Comparative analysis of demographics and clinical outcomes in patients with pemphigus vulgaris and foliaceus with high versus normal anti-desmoglein levels post-complete remission.

Aryanian Z, Balighi K, Azizpour A, RafieeTehrani N, Khayyat A, Hatami P Arch Dermatol Res. 2025; 317(1):562.

PMID: 40085247 DOI: 10.1007/s00403-025-04025-0.

Complementary Chinese Herbal Medicine Therapy Improves Survival in Patients With Pemphigus: A Retrospective Study From a Taiwan-Based Registry.

Wu P, Li T, Chen S, Chen C, Chiou J, Lin M Front Pharmacol. 2020; 11:594486.

PMID: 33362549 PMC: 7756119. DOI: 10.3389/fphar.2020.594486.

Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity.

Delavarian Z, Layegh P, Pakfetrat A, Zarghi N, Khorashadizadeh M, Ghazi A J Clin Exp Dent. 2020; 12(5):e440-e445.

PMID: 32509225 PMC: 7263783. DOI: 10.4317/jced.56289.

Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity.

Lin N, Liu Q, Wang M, Wang Q, Zeng K PeerJ. 2018; 6:e5388.

PMID: 30083474 PMC: 6078064. DOI: 10.7717/peerj.5388.

References

Ishii K, Amagai M, Hall R, Hashimoto T, Takayanagi A, Gamou S . Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997; 159(4):2010-7. View

Schmidt E, Dahnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S . Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol. 2010; 19(5):458-63. DOI: 10.1111/j.1600-0625.2010.01069.x. View

Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P . ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009; 145(5):529-35. DOI: 10.1001/archdermatol.2009.9. View

Harman K, Seed P, Gratian M, Bhogal B, Challacombe S, Black M . The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001; 144(4):775-80. DOI: 10.1046/j.1365-2133.2001.04132.x. View

Mutasim D . Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol. 2004; 51(6):859-77. DOI: 10.1016/j.jaad.2004.02.013. View

Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T . The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999; 40(2 Pt 1):167-70. DOI: 10.1016/s0190-9622(99)70183-0. View

Daneshpazhooh M, Kamyab K, Kalantari M, Balighi K, Naraghi Z, Shamohammadi S . Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris. Clin Exp Dermatol. 2013; 39(1):41-7. DOI: 10.1111/ced.12187. View

Joly P, Litrowski N . Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011; 29(4):432-6. DOI: 10.1016/j.clindermatol.2011.01.013. View

Bystryn J, Rudolph J . Pemphigus. Lancet. 2005; 366(9479):61-73. DOI: 10.1016/S0140-6736(05)66829-8. View

10.

Akman A, Uzun S, Alpsoy E . Immunopathologic features of pemphigus in the east Mediterranean region of Turkey: a prospective study. Skinmed. 2010; 8(1):12-6. View

11.

Avgerinou G, Papafragkaki D, Nasiopoulou A, Markantoni V, Arapaki A, Servitzoglou M . Correlation of antibodies against desmogleins 1 and 3 with indirect immunofluorescence and disease status in a Greek population with pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2012; 27(4):430-5. DOI: 10.1111/j.1468-3083.2011.04428.x. View

12.

Harman K, Gratian M, Bhogal B, Challacombe S, Black M . A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol. 2000; 143(2):343-8. DOI: 10.1046/j.1365-2133.2000.03660.x. View

13.

Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, Mansoori P, Taheri A, Firooz A . Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. J Eur Acad Dermatol Venereol. 2007; 21(10):1319-24. DOI: 10.1111/j.1468-3083.2007.02254.x. View

14.

Cheng S, Kobayashi M, Tanikawa A, Amagai M, Nishikawa T . Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002; 147(2):261-5. DOI: 10.1046/j.1365-2133.2002.04838.x. View

15.

Harman K, Albert S, Black M . Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003; 149(5):926-37. DOI: 10.1111/j.1365-2133.2003.05665.x. View

16.

Sharma V, Prasad H, Khandpur S, Kumar A . Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris. Int J Dermatol. 2006; 45(5):518-22. DOI: 10.1111/j.1365-4632.2006.02593.x. View

17.

Belloni-Fortina A, Faggion D, Pigozzi B, Peserico A, Bordignon M, Baldo V . Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol. 2010; 2009:187864. PMC: 2798087. DOI: 10.1155/2009/187864. View

18.

Kwon E, Yamagami J, Nishikawa T, Amagai M . Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol. 2008; 22(9):1070-5. DOI: 10.1111/j.1468-3083.2008.02715.x. View

19.

Amagai M, Hashimoto T, Green K, Shimizu N, Nishikawa T . Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol. 1995; 104(6):895-901. DOI: 10.1111/1523-1747.ep12606168. View

20.

Anand V, Khandpur S, Sharma V, Sharma A . Utility of desmoglein ELISA in the clinical correlation and disease monitoring of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2011; 26(11):1377-83. DOI: 10.1111/j.1468-3083.2011.04294.x. View